Recent Finacing
Recent Raise
Anbogen Therapeutics, a Taipei-based clinical-stage biotech developing precision small-molecule oncology drugs: ABT-101, HER2 exon 20 insertion TKI for NSCLC; ABT-301, immune potentiator with PD‑1 inhibitors for MSS CRC.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at AnBogen Therapeutics.
